玻璃体切割联合内界膜剥除治疗糖尿病性黄斑水肿

doi:10.3760/cma.j.issn.1674-845X.2019.06.006

摘要
图/表
参考文献(22)
相关文章 (15)

全文: PDF 931KB HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要

评估玻璃体切割联合内界膜剥除对糖尿病性黄斑水肿（DME）的疗效。方法：回顾性病例对照研究。2014年6月至2017年1月间因糖尿病视网膜病变合并玻璃体积血或增殖病变于温州医科大学附属眼视光医院杭州院区行玻璃体切割手术治疗，且术前或术中经光学相干断层扫描（OCT）检查确诊合并DME的患者31例（33眼）纳入研究。16例（18眼）术中联合内界膜剥除作为剥膜组，15例（15眼）仅接受玻璃体切割手术治疗者作为对照组。所有手术均由同一医师主刀完成。术后1、3个月随访时复查OCT，对比观察黄斑中心厚度（CMT）和视力的术后变化情况。随访中CMT和最佳矫正视力（BCVA）比较采用重复测量方差分析，组间CMT和BCVA比较采用独立样本t检验。结果：手术前，手术后1、3个月2组间比较LogMAR视力总体差异有统计学意义（F=15.93，P<0.001）。术后 1个月时剥膜组BCVA高于对照组（t=2.55，P=0.02），但术后3个月时2组间差异无统计学意义（t=0.82， P=0.42）。手术前，手术后1、3个月CMT总体差异无统计学意义（F=2.85，P=0.065）。术后1、3个月时，剥膜组的CMT均低于对照组，2组间差异均有统计学意义（t=2.24，P=0.03；t=3.79，P=0.001）。术后1个月时，剥膜组有效（与术前比CMT减少20%以上）、无效（变化不超过20%）及恶化（增厚超过 20%）的例数分别为8、6、4例，术后3个月时则分别为11、5、2例，与对照组相比，术后1个月时组间差异无统计学意义（Z=-1.687，P=0.092），术后3个月时剥膜组DME改善有效比例明显高于对照组，组间差异有统计学意义（Z=-2.177，P=0.029）。结论：对于非牵拉性DME，内界膜剥除有助于术后早期DME消退。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：糖尿病性黄斑水肿, 玻璃体切割术, 内界膜

Abstract：

To investigate the effects of vitrectomy combined with internal limiting membrane (ILM) peeling indiabetic macular edema (DME). Methods: In this retrospective clinical study, 33 eyes of 31 patients with DME confirmed preoperatively or intraoperatively by optical coherence tomography (OCT) were included. All patients underwent vitrectomy for dense vitreous hemorrhages due to diabetic retinopathy or proliferative diabetic retinopathy between June 2014 and January 2017 at the Eye Hospital,Wenzhou Medical University. A total of 16 patients (18 eyes) with vitrectomy and ILM peeling were in the ILM-removed group, 15 eyes of 15 patients with vitrectomy only were in the control group. All the surgeries were performed by the same surgeon. All subjects underwent OCT examination at 1 month and 3 months postoperatively. The central macular thickness (CMT) and visual outcomes between the two groups were analyzed relative to each other. The data were analyzed by repeated measures analysis and t-tests. Results: Before the therapy, and at one and three months after therapy, the total difference of best corrected visual acuity (BCVA) between the two groups was statistically significant (F=15.93, P<0.001). The BCVA in the ILM-removed group was higher than the control group at one month after therapy (t=2.55, P=0.02). However, there was no significant difference between the two groups in terms of BCVA at three months after therapy (t=0.82, P=0.42). Before the therapy, and at one and three months after therapy, the total difference of CMT between the two groups was not statistically significant (F=2.85, P=0.065). At both one month and three months after therapy, the CMT in the ILM-removed group was lower than the control group (t=2.24, P=0.03; t=3.79, P=0.001). At 1 month postoperatively, the subjects of effectiveness (a decrease in CMT by at least 20%), ineffectiveness (a change in CMT by <20%) and deterioration (an increase in CMT by more than 20%) were 8, 6 and 4 respectively, while the subjects were 11, 5 and 2 respectively at 3 months after therapy. There was no significant difference from the control group (Z=-1.687, P=0.092) at one month after therapy, but there was a significant difference at three months after therapy (Z=-2.177, P=0.029). Conclusions: The removal of ILM contributes to the resolution of nontractional DME at an early stage after therapy.

Key words： diabetic macular edema vitrectomy internal limiting membrane

收稿日期: 2018-01-20

基金资助:

浙江省科技厅重大专项（2013C03048-3）；国家科技重大专项（2014ZX09303301）；浙江省医药卫生平台项目（2016RCB012）

通讯作者: 沈丽君（ORCID：0000-0001-9106-5456），Email：slj@mail.eye.ac.cn

引用本文:

赵士鑫吴韩飞沈丽君毛剑波陈亦棋陶继伟. 玻璃体切割联合内界膜剥除治疗糖尿病性黄斑水肿[J]. 中华眼视光学与视觉科学杂志, 2019, 21(6): 433-438. Shixin Zhao, Hanfei Wu, Lijun Shen, Jianbo Mao, Yiqi Chen, Jiwei Tao. The Treatment of Vitrectomy Combined with Internal Limiting Membrane Peeling in Diabetic Macular Edema. Chinese Journal of Optometry Ophthalmology and Visual science, 2019, 21(6): 433-438. DOI: 10.3760/cma.j.issn.1674-845X.2019.06.006

链接本文:

https://www.cjoovs.com/CN/ 10.3760/cma.j.issn.1674-845X.2019.06.006 或 https://www.cjoovs.com/CN/Y2019/V21/I6/433

[1]	Hartley KL, Smiddy WE, Flynn HW Jr, et al. Parsplana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina, 2008, 28(3): 410-419. DOI: 10.1097/
	IAE.0b013e31816102f2.
[2]	Kim YM, Chung EJ, Byeon SH, et al. Pars plana vitrectomy with internal limiting membrane peeling compared with intravitreal triamcinolone injection in the treatment of diabetic macular edema. Ophthalmologica, 2009, 223(1): 17-23. DOI: 10.1159/000161878.
[3]	Ulrich JN. Pars Plana vitrectomy with internal limiting membrane peeling for nontractional diabetic macular edema. Open Ophthalmol J, 2017, 31(11): 5-10. DOI: 10.2174/187. 4364101711010005.
[4]	Kumagai K, Ogino N, Furukawa M, et al. Internal limiting membrane peeling in vitreous surgery for diabetic macular edema. Nippon Ganka Gakkai Zasshi, 2002, 106(9): 590-594.
[5]	Stefansson E, Landers MB, Wolbarsht ML. Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Trans Am Ophthalmol Soc, 1981, 79: 307-334.
[6]	Holekamp NM, Shui YB, Beebe DC. Vitrectomy surgery increases oxygen exposure to the lens: A possible mechanism for nuclear cataract formation. Am J Ophthalmol, 2005, 139(2): 302-310. DOI: 10.1016/j.ajo.2004.09.046.
[7]	Park JH, Woo SJ, Ha YJ, et al. Effect of vitrectomy on macular microcirculation in patients with diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol, 2009, 247(8): 1009- 1017. DOI: 10.1007/s00417-009-1062-1.
[8]	Gandorfer A, Haritoglou C, Kampik A. Toxicity of indocyanine green in vitreoretinal surgery. Dev Ophthalmol, 2008, 42: 69-81. DOI: 10.1159/000138974.
[9]	赵敏婕, 郑志．抗血管内皮生长因子药物治疗糖尿病视网膜病变的研究进展. 中华眼视光学与视觉科学杂志, 2016, 18(9): 573-576． DOI: 10．3760/cma.j.issn.1674-845X.2016.09. 016.
[10]	Alvi R, Memon MS, Shera S, et al. Visual outcome of laser treatment in diabetic macular edema: Study from an Urban Diabetes Care Center. Pak J Med Sci, 2016, 32 (5): 1229-1233. DOI: 10.12669/pjms.325.10597.
[11]	Jackson TL, Nicod E, Angelis A, et al. Pars plana vitrectomy for diabetic macular edema: A Systematic Review, Meta-Analysis, and Synthesis of Safety Literature. Retina, 2017, 37(5): 886- 895. DOI: 10.1097/IAE.0000000000001280.
[12]	Dehghan MH, Salehipour M, Naghib J, et al. Pars plana vitrectomy with internal limiting membrane peeling for refractory diffuse diabetic macular edema. J Ophthalmic Vis Res, 2010, 5(3): 162- 167.
[13]	Yamamoto T, Hitani K, Sato Y, et al. Vitrectomy for diabetic macular edema with and without internal limiting membrane removal. Ophthalmologica, 2005, 219(4): 206-213. DOI: 10.1159/000085729.
[14]	Kimura T, Kiryu J, Nishiwaki H, et al. Efficacy of surgical removal of the internal limiting membrane in diabetic cystoid macular edema. Retina, 2005, 25(4): 454-461.
[15]	Ghassemi F, Bazvand F, Roohipoor R, et al. Outcomes of vitrectomy, membranectomy and internal limiting membrane peeling in patients with refractory diabetic macular edema and non-tractional epiretinal membrane. J Curr Ophthalmol, 2016, 28(4): 199-205. DOI: 10.1016/j.joco.2016.08.006.
[16]	Kumagai K, Hangai M, Ogino N, et al. Effect of internal limiting membrane peling on long-term visual outcomes for diabetic macular edema. Retina, 2015, 35(7): 1422-1428. DOI: 10.1097/IAE.0000000000000497.
[17]	Hoerauf H, Brüggemann A, Muecke M, et al. Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloid removal. A prospective randomized trial. Graefes Arch Clin Exp Ophthalmol, 2011, 249(7): 997-1008. DOI: 10.1007/s00417-010-1610-8.
[18]	Yanyali A, Horozoglu F, Celik E, et al. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina, 2007, 27(5): 557-566. DOI: 10.1097/01.iae.0000249390.61854.d5.
[19]	Matsunaga N, Ozeki H, Hirabayashi Y, et al. Histopathologic evaluation of the internal limiting membrane surgically excised from eyes with diabetic maculopathy. Retina, 2005, 25(3): 311- 316.
[20]	Patel JI, Hykin PG, Schadt M, et al. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina, 2006, 26(1): 5-13.
[21]	Ehlers JP, Griffith JF, Srivastava SK. Intraoperative OCT during vitreoretinal surgery for dense vitreous hemorrhage in the PIONEER Study. Retina, 2015, 35(12): 2537-2542. DOI: 10.1097/IAE.0000000000000660.
[22]	Michalewska Z, Bednarski M, Michalewski J, et al. The role of ILM peeling in vitreous surgery for proliferative diabetic retinopathy complications. Ophthalmic Surg Lasers Imaging Retina, 2013, 44(3): 238-242. DOI: 10.3928/23258160-20130503- 05.